Previous 10 | Next 10 |
BridgeBio Pharma ( NASDAQ: BBIO ) said the first patient was dosed in its phase 1 trial of oral therapy BBP-671 being developed to treat conditions caused by coenzyme A (CoA) deficiencies. Coenzyme A plays a role in metabolism via synthesis and oxidation of fatty ...
- Initial data readout for patients with PA and MMA expected in the first half of 2023 - Interim data from healthy individuals, reported earlier this year, showed that BBP-671 was detected in plasma and cerebrospinal fluid (CSF) at concentrations above predicted therapeutic th...
- NULIBRY is the first and only approved therapy in the United States (U.S.) and in Israel to treat patients with MoCD Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants with a median overall survival age of about four years - NULIB...
BridgeBio Pharma press release ( NASDAQ: BBIO ): Q2 GAAP EPS of -$0.07 beats by $0.65 . Revenue of $73.75M (+36.5% Y/Y) beats by $48.75M . Cash, cash equivalents and marketable securities, excluding restricted cash, at Q2 end increased by $55.1M when compared t...
- Reported positive interim Phase 2 data for infigratinib in achondroplasia demonstrating a mean increase in annualized height velocity (AHV) of 1.52 cm/year among all Cohort 4 children 5 years of age and older, and announced addition of a 5 th cohort to the trial ...
Gainers: Applied DNA Sciences ( APDN ) +93% . Alnylam Pharmaceuticals ALNY +55% . Poseida Therapeutics PSTX +47% . NeuroOne Medical Technologies ( NMTC ) +31% . Sonoma Pharmaceuticals ( SNOA ) +21% . Losers: BridgeBio Pharma B...
Alnylam Pharmaceuticals ( ALNY ) made headlines across the biotech space on Wednesday after the RNAi therapeutics company announced that its ATTR amyloidosis therapy patisiran met the main goal in a Phase 3 trial. The much-awaited data readout propelled Alnylam ( ALNY ...
Hydrofarm Holdings Group HYFM -27% on slashed guidance amid hydroponics recession . Meihua International Medical Technologies ( MHUA ) -13% . MDJM ( MDJH ) -21% . Match Group MTCH -21% on Q2 earnings release . Horizon Therapeutics Public...
Shares of BridgeBio Pharma ( NASDAQ: BBIO ) are up 11% in premarket trading after reporting positive phase 2 results for infigratinib in children with achondroplasia. At the highest dose level (0.128 mg/kg once daily), mean increase in annualized height veloci...
Virax Biolabs Group ( VRAX ) +40% on launch of real-time PCR test for monkeypox in Europe. 36Kr Holdings ( KRKR ) +14% . InflaRx ( IFRX ) +12% Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Crit...
News, Short Squeeze, Breakout and More Instantly...
2024-07-09 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- BridgeBio has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living with LGMD2I/R9, with top-line results from the interim analysis expected in 2025 - Recent Type C interactions with U.S. Food and Drug Administration (FDA) focu...